Test ID LLTOF Leukemia and Lymphoma Phenotyping, Technical Only
Useful For
Evaluating lymphocytoses of undetermined etiology
Identifying B- and T-cell lymphoproliferative disorders involving blood and bone marrow
Distinguishing acute lymphoblastic leukemia from acute myeloid leukemia (AML)
Immunologic subtyping of acute leukemias
Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma
Distinguishing between malignant lymphoma and acute leukemia
Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia
Recognizing AML with minimal morphologic or cytochemical evidence of differentiation
Recognizing monoclonal plasma cells
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
VBETA | TCR V-BETA | No | No |
FIRST | Flow Cytometry, Cell Surface, First | No, (Bill Only) | No |
ADD1 | Flow Cytometry, Cell Surface, Addl | No, (Bill Only) | No |
FCINT | Flow Cytometry Interp, 2-8 Markers | No, (Bill Only) | No |
FCIMS | Flow Cytometry Interp, 9-15 Markers | No, (Bill Only) | No |
FCINS | Flow Cytometry Interp,16 or greater | No, (Bill Only) | No |
Testing Algorithm
Note: This test is only available to clients who have MayoAccess or MayoLink
The client is responsible for the interpretation and billing of the professional component; Mayo Clinic will bill the technical component only.
For blood bone marrow, and fluid specimens, the triage panel evaluates monotypic B-cells by kappa and lambda light chain expression, increased numbers of blasts by CD34 and CD45 expression along with side scatter gating, and increased plasma cells by CD45 expression and side scatter gating. The panel also includes antibodies to assess the number of CD3-positive T cells and CD16-positive/CD3-negative natural killer (NK) cells present. This panel also determines if there is an increase in the number of T cells that aberrantly coexpress CD16, an immunophenotypic feature of T-cell granular lymphocytic leukemia.
For tissue specimens, the triage panel includes evaluation for monotypic B cells by kappa and lambda light chain expression, CD5, CD10, CD19, CD20, and CD23. Increased numbers of blasts and plasma cells are identified by CD45 expression along with side scatter gating. The panel can also evaluate T cells with CD3, CD5, and CD7. Additionally, viability is assessed on all tissue specimens using 7-AAD exclusion.
This panel, together with the provided clinical history and morphologic review will determine if additional testing is required. If additional testing is needed, it will be added per algorithm to fully characterize a disease state with a charge per unique antibody tested.
Cases requiring the granular lymphocytic leukemia flow panel or V-beta panel will have an interpretation added and performed by a Mayo Clinic pathologist.
If no abnormalities are detected by the triage panel, no further flow cytometric assessment will be performed unless otherwise indicated by specific features of the clinical presentation or prior laboratory results.
Bone marrow specimens being evaluated for possible involvement by a myelodysplastic syndrome (MDS) or a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) including chronic myelomonocytic leukemia (CMML) should be ordered as MYEFL / Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow, not this test.
The following algorithms are available in Special Instructions:
-Malignant Lymphoma, Guideline for Bone Marrow Staging Studies
-Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up
Special Instructions
Method Name
Immunophenotyping
Reporting Name
Leukemia/Lymphoma; Tech Only FlowSpecimen Type
VariesSpecimen must arrive within 48 hours of collection for spinal fluid, 96 hours for peripheral blood and bone marrow, or 72 hours for fluids.
This test is not appropriate for and cannot support diagnosis of sarcoidosis, hypersensitivity pneumonitis, interstitial lung diseases, or differentiating between pulmonary tuberculosis and sarcoidosis (requests for CD4/CD8 ratios). Specimens sent for these purposes will be rejected.
Bronchoalveolar lavage specimens submitted for evaluation for leukemia or lymphoma are appropriate to send for this test.
The following information is required:
1. Pertinent clinical history including reason for referral or clinical indication
2. Clinical or morphologic suspicion
3. Specimen source
4. Date and time of collection
Forms:
1. Hematopathology Patient Information Sheet (T676) in Special Instructions
2. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
Hematopathology/Cytogenetics Test Request Form (T726) (http://www.mayomedicallaboratories.com/it-mmfiles/hematopathology-request-form.pdf)
Submit only 1 of the following specimens:
Specimen Type: Blood
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Heparin, EDTA
Specimen Volume: 10 mL
Collection Instructions:
1. Do not transfer blood to other containers.
2. Include 5 to 10 unstained blood smears, if possible.
3. Label specimen as blood.
Specimen Stability Information: Ambient <96 hours/Refrigerated ≤96 hours
Specimen Type: Bone marrow
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: ACD, Heparin, EDTA
Specimen Volume: 1-5 mL
Collection Instructions:
1. Submission of bilateral specimens is not required.
2. Include 5 to 10 unstained bone marrow aspirate smears, if possible.
3. Label specimen as bone marrow.
Specimen Stability Information: Ambient <96 hours/Refrigerated ≤96 hours
Additional Information: If cytogenetic tests are also desired when drawing LCMS / Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, an additional specimen should be submitted. It is important that the specimen be obtained, processed, and transported according to instructions for the other required test.
Specimen Type: Fluid
Sources: Serous effusions
Container/Tube: Body fluid container
Specimen Volume: 20 mL
Collection Instructions:
1. If possible, the fluids other than spinal fluid should be anticoagulated with heparin (1 U/mL of fluid).
2. The volume of fluid necessary to phenotype the lymphocytes or blasts in serous effusions depends upon the cell count in the specimen. Usually 20 mL of pleural or peritoneal fluid is sufficient. Smaller volumes can be used if there is a high cell count.
3. Label specimen with fluid type.
Specimen Stability Information: Refrigerated <72 hours/Ambient ≤72 hours
Specimen Type: Spinal fluid
Container/Tube: Sterile vial
Specimen Volume: 1-1.5 mL
Collection Instructions:
1. An original cytospin preparation (preferably unstained) must be included with the spinal fluid specimen so correlative morphologic evaluation can occur.
2. The volume of fluid necessary to phenotype the lymphocytes or blasts in spinal fluid depends upon the cell count in the specimen. A cell count should be determined and submitted with the specimen. Usually 1 to 1.5 mL of spinal fluid is sufficient. Smaller volumes can be used if there is a high cell count. If cell count is <10 cells/mcL, a larger volume of spinal fluid may be required. When cell counts drop below 5 cells/mcL, the immunophenotypic analysis may not be successful.
3. Label specimen as spinal fluid.
Specimen Stability Information: Refrigerated <48 hours/Ambient ≤48 hours
Additional Information: Spinal fluid cell and differential counts are required.
Specimen Type: Tissue
Container/Tube: Sterile container with 15 mL of tissue culture medium (eg, Hank's balanced salt solution [Supply T132], RPMI, or equivalent)
Specimen Volume: 5 mm(3) or larger biopsy
Collection Instructions:
1. Send intact specimen (do not mince).
2. Specimen cannot be fixed.
Additional Information:
1. Date, time of collection, tissue type, and location are required.
2. A pathology/diagnostic report including the client surgical pathology case number, a brief history, reason for referral or clinical suspicion are required before the specimen will be processed.
Specimen Stability Information: Ambient <96 hours/Refrigerated ≤96 hours
Specimen Minimum Volume
Blood: 3 mL/Bone Marrow: 1 mL/Fluid from Serous Effusions: 5 mL/Spinal Fluid: 1 mL/Tissue: 5 mm(3) or larger biopsy
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Varies | Varies |
Clinical Information
Immunophenotyping hematopoietic specimens can help resolve many differential diagnostic problems posed by the clinical or morphologic features. This test is appropriate for hematopoietic specimens only.
This is a technical only test and does not include interpretation unless reflex testing is performed. At any point, clients may request to have a Mayo Clinic hematopathologist provide an interpretation at an additional charge.
Reference Values
Not applicable
Cautions
Specimens will be initially triaged to determine which, if any, of the immunophenotyping panels should be performed.
Day(s) Performed
Specimens are processed and reported Monday through Saturday
Report Available
1 dayPerforming Laboratory

Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
88184-Flow cytometry; first cell surface, cytoplasmic or nuclear marker
88185-Flow cytometry; additional cell surface, cytoplasmic or nuclear marker (each)
Additional CPTs may be added if consultative help is needed with the case, or algorithm dictates Mayo consultant involvement.
88187-Flow cytometry interpretation, 2 to 8 markers (if appropriate)
88188-Flow cytometry interpretation, 9 to 15 markers (if appropriate)
88189-Flow cytometry interpretation, 16 or more markers (if appropriate)